Neurospesific proteins in the serum of patients with brain tumors and neurological diseases of non-tumor ethiology
https://doi.org/10.25016/2541-7487-2016-0-3-90-95
Abstract
Results of comparative immunoenzymatic evaluation of neurospecific proteins S-100 and GFAP in blood serum of 52 apparently healthy persons, 175 neurooncologic patients, and 38 patients with brain pathology of non-oncologic origin (neurodegenerative and cerebrovascular diseases) are presented. It was found that the frequency of detection and serum concentration of GFAP was statistically significantly higher in patients with primary malignant brain tumors than in apparently healthy persons or patients with benign tumors. Serum S-100 concentration was statistically significantly higher in patients with primary malignant and metastatic cerebral tumors than in those with neurodegenerative and cerebrovascular diseases. Significant increase of serum GFAP concentration was revealed in patients with primary malignant brain tumors as compared to patients with cerebral metastatic or benign neoplasms and those with non-tumor pathology. GFAP levels were maximal in patients with glioblastoma - a tumor with the highest grade of malignancy. These results suggest a relationship between high serum neurospecific proteins and disrupted blood-brain barrier in case of malignant brain neoplasms.
About the Authors
Nina Vasilievna Lyubimova
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Yuri Sergeevich Timofeev
Moscow State University of Medicine and Dentistry named after A. I. Evdokimov
Russian Federation
Russian Federation
Nikolay Evgenievich Kushlinskii
N.N. Blokhin Russian Cancer Research Center; Moscow State University of Medicine and Dentistry named after A. I. Evdokimov
Russian Federation
Russian Federation
References
1. Любимова Н. В., Томс М. Г., Попова Е. Е. [и др.]. Нейроспецифические белки в сыворотке крови больных с опухолями головного мозга // Бюл. эксперим. биологии и медицины. 2010. Т. 150, № 12. С. 678-681.
2. Baimhridge K. G., Celio M. R., Rogers J. H. Calcium-binding proteins in the nervous system // J. Neurosci. 1992. Vol. 15, N 8. P. 303-308.
3. Blennow K., Wallin A., Chong J. K. Cerebrospinal fluid ‘neuronal thread protein’ comes from serum by passage over the blood-brain barrier // Neurodegeneration. 1995. Vol. 4, N 2. P. 187-193.
4. Brommeland T., Rosengren L., Fridlund S. [et al.]. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas // Acta Neurol. Scand. 2007. Vol. 116, N 6. P. 380-384.
5. Eng L. F. The glial fibrillary acidic protein: the major protein constitutent of glialfillaments // Scand. J. Immunology. 1982. Vol. 15. Suppl. 9. P. 41-51.
6. Farrell C. Z., Risan W. Normal and abnormal development of the blood-brain barrier // Micrisc. Res. Tech. 1994. Vol. 27, N 6. P. 495-506.
7. Foerch C., Niessner M., Back T. [et al.]. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke // Clin Chem. 2012. Vol. 58, N 1. P 237-245.
8. Gállego Pérez-Larraya J., Paris S. [et al.]. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma // Cancer. 2014. Vol. 120, N 24. P 3972-3980.
9. Jung C. S., Foerch C., Schänzer A. [et al.]. Serum GFAP is a diagnostic marker for glioblastoma multiforme // Brain. 2007. Vol. 130, Pt 12. P 3336-3341.
10. Kiviniemi A., Gardberg M., Frantzén J. [et al.]. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival // J. Neurooncol. 2015. Vol. 124, N 2. P 237-45.
11. Lamers K. J., van Engelen B. G., Gabreels F J. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders // Acta Neurol. Scand. 1995. Vol. 92, N 3. P 247-251.
12. Long D. M. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors // J. Neurosurg. 1996. Vol. 32, N 6. P 127-144.
13. Mayer C. A., Brunkhorst R., Niessner M., Pfeilschifter W., Steinmetz H., Foerch C. Blood levels of glial fibrillary acidic protein (GFAP) in patients with neurological diseases // PLoS One. 2013. Vol. 8, N 4. e62101. doi: 10.1371/journal.pone.0062101.
14. Missler U., Wiesmann M. Measurement of S-100 protein in human blood and cerebrospinal fluid: analytical method and preliminary clinical results // Eur. J. Clin. Chem. Clin. Biochem. 1995. Vol. 33, N 10. P 743-748.
15. Missler U., Wiesmann M., Friedrich C., Kaps M. S-100 protein and NSE concentration in blood as indicators of infarction volume and prognosis in acute ischemic stroke // Stroke. 1997. Vol. 28, N 10. P 1956-1960.
16. Pang X., Min J., Liu L. [et al.]. S 100 protein as a possible participant in the brain metastasis of NSCLC // Med. Oncol. 2012. Vol. 29, N 4. P 2626-2632.
17. Petzold A. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease // Brain Res. 2015. Vol. 1600. P 17-31. doi: 10.1016/ j.brainres.
18. Takala R. S., Posti J. P., Runtti H. [et al.]. Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 as Outcome Predictors in Traumatic Brain Injury // World Neurosurg. 2016. Vol. 87. P 8-20. doi: 10.1016/jwneu.
19. Tichy J., Spechtmeyer S., Mittelbronn M. [et al.]. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma // J. Neurooncol. 2016. Vol. 126, N 2. P 361-369.
20. Wilhelmsson U., Eliasson C., Bjerkvig R., Pekny M. Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression // Oncogene. 2003. Vol. 22, N 22. P 3407-3411.
Review
For citations:
Lyubimova N.V., Timofeev Yu.S., Kushlinskii N.E. Neurospesific proteins in the serum of patients with brain tumors and neurological diseases of non-tumor ethiology. Medicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations. 2016;(3):90-95. (In Russ.) https://doi.org/10.25016/2541-7487-2016-0-3-90-95
Views:
778
Email this article 